摘要
目的:分析mdm2、p53在胶质瘤中的表达意义及与临床病理特征的关系。方法:选取我院2012年4月至2013年4月期间存档的54例胶质瘤石蜡标本以及相应瘤旁正常组织标本作为研究对象,将胶质瘤石蜡标本作为观察组,将瘤旁正常组织标本作为对照组。采用LSAB免疫组化法测量两组样本中mdm2、p53蛋白表达水平,分析上述蛋白在胶质瘤患者疾病发生及发展中的具体意义。结果:胶质瘤石蜡标本中mdm2、p53阳性表达率显著高于相应瘤周正常组织标本(P<0.05);Ⅲ、Ⅳ期胶质瘤患者p53、mdm2阳性表达率及"+++"表达率显著高于Ⅰ、Ⅱ期患者(P<0.05);p53、mdm2高表达患者术后生存时间均显著低于p53、mdm2低表达患者(P<0.05);p53、mdm2阳性表达率均与疾病分期以及淋巴结转移有明显相关性(P<0.05);mdm2、p53蛋白在胶质瘤中呈正相关(r=0.713,P<0.05)。结论:mdm2通过调节p53蛋白的表达对胶质瘤发生发展起调控作用,Ⅲ、Ⅳ期疾病分期及淋巴结转移等因素均对mdm2、p53在肿瘤细胞中的异常表达有相关性,临床中可针对上述指标阳性表达程度预测患者病情发展,并为后续治疗方案的制定及改善提供相应的数据支持。
Objective:To analyze the significance of mdm2 and p53 expression in glioma and its relationship with clinical features.Methods:From April 2012 to April 2013,54 paraffin wax specimens of glioma and normal tissues adjacent to the tumor were selected as the study objects.Paraffin specimens of gliomas were used as observation group and normal tissues adjacent to tumor as control group.The expression level of mdm2 and p53 was measured by LSAB immunohistochemical method.The significance of above-mentioned proteins in the occurrence and development of glioma disease was analysed.Results:The positive rate of mdm2 p53 in paraffin tissues of gliomas was significantly higher than that in normal tissues around the tumor(P<0.05).The positive rate of p53/mdm2 and "+++" expression in patients with stage Ⅲ and Ⅳgliomas were significantly higher than those in patients with stage Ⅰ and Ⅱ(P<0.05).The survival time of patients with high expression of p53 and mdm2 was significantly lower than that of patients with low expression of p53,and mdm2(P<0.05).There was positive correlation between mdm2 and p53 protein in glioma(r=0.713,P<0.05).Conclusion:mdm2 regulates the development of glioma by regulating the expression of p53 protein.The stages of stage Ⅲ and Ⅳ,lymph node metastasis and other factors are related to the abnormal expression of mdm2 and p53 in tumor cells.In clinic,the positive expression level of the above indexes can predict the development of the patient’s condition,and provide the corresponding data support for the formulation and improvement of the follow-up treatment plan.
作者
汤计磊
范月超
Tang Jilei;Fan Yuechao(Xuzhou University of Medical Sciences Graduate School,Jiangsu Xuzhou 221000,China;The Cranial Base Tumor Ward of Neurosurgery Department,Xuzhou Medical University Affiliated Hospital,Jiangsu Xuzhou 221000,China)
出处
《现代肿瘤医学》
CAS
2019年第18期3219-3223,共5页
Journal of Modern Oncology
